| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 10-Q |
| 19 Oct 2026 |
8-K: Other Events
Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform |
| 14 Aug 2026 | 10-Q |
| 15 May 2026 | 10-Q |
| 04 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF MARKER THERAPEUTICS, INC. |
| 20 Mar 2026 | DEFA14A |
| 20 Mar 2026 | ARS |
| 20 Mar 2026 |
Proxy statement: annual meeting on May 1, 2026
say-on-pay vote |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses |
| 18 Mar 2026 | 10-K |
| 10 Mar 2026 | FORM PRE 14A |
| 09 Feb 2026 |
8-K: Shareholder Director Nominations
On February 9, 2026, the Board of Directors of Marker Therapeutics, Inc. (the “Company”) determined it is in the best interest of the Company to schedule Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) for May 1... |
| 19 Nov 2025 |
Form 4: Knobil Katharine, Director
Granted 221,741 Stock Option (Right to Buy) |
| 19 Nov 2025 |
Form 4: Eansor Norman David, Director
Granted 221,741 Stock Option (Right to Buy) |
| 19 Nov 2025 |
Form 4: Elms Steve, Director
Granted 221,741 Stock Option (right to buy) |
| 17 Nov 2025 | SCHEDULE 13D/A |
| 14 Nov 2025 | SCHEDULE 13G/A |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma |
| 13 Nov 2025 | 10-Q |
| 05 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Houston, TX — November 5, 2025 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and s... |
Loading...